Skip to main content

Table 1 Characteristics of patients

From: Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?

  SLE group (n = 69) Non-SLE group (n = 73) p values
Age (SD) (years) 75.7 ± 7.1 78.2 ± 6.2 0.02
Sex (Men/Women) 60 (87.0%) /9 (13.0%) 60 (82.2%) /13 (17.8%) 0.43
Comorbidities
 Hypertension 41 (59.4%) 53 (72.6%) 0.10
 Diabetes mellitus 17 (24.6%) 26 (35.6%) 0.15
 Hyperlipidemia 30 (43.5%) 35 (47.9%) 0.59
 Ischemic heart disease 28 (40.6%) 29 (39.7%) 0.92
 Cerebrovascular disease 28 (40.6%) 26 (35.6%) 0.54
 Renal disease (eGFR < 30 mL/min/1.73m2) 1 (1.4%) 1 (1.4%) 0.97
Antithrombotic agent    0.50
 Single antiplatelets 32 (46.4%) 37 (50.7%)  
 Aspirin 15 20  
 Cilostazol 6 5  
 Thienopyridine 11 12  
 Single anticoagulants 16 (23.2%) 20 (27.4%)  
 Warfarin 7 7  
 DOACs 9 13  
 Multiple therapy 21 (30.4%) 16 (21.9%)  
 Anticoagulant + antiplatelet 9 7  
 DAPT 10 8  
 Triplet therapy 2 1  
Interruption of antithrombotic agents 55 (79.7%) 41 (56.1%) < 0.05
 Heparin replacement 12 0  
 Aspirin or cilostazol replacement 9 10  
Acid blocker    < 0.05
 Esomeprazole 40 (58.0%) 1 (1.4%)  
 Vonoprazan 29 (42.0%) 72 (98.6%)  
Multiple lesions 11 (15.9%) 14 (19.1%) 0.61
  1. *SD standard deviation, DOACs direct oral anticoagulants, DAPT dual antiplatelet therapy